For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 87 |
| Referral date | 01 July 2009 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Paul Cooney |
| Executive Lead: | Peter Littlejohns |
| Project manager: | Kate Moore |
| Technical Lead: | Joao Vieira |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Following on from information provided to NICE by the company in August 2019 the appraisal of Kidney transplantation – belatacept was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 26 February 2016 | Discontinued. For information belatacept was considered within the MTA for Kidney transplantation (adults) - immunosuppressive therapy (ID456), rather than being appraised as a separate STA. This MTA has now published as TA481 |
For further information on our processes and methods, please see our CHTE processes and methods manual